The Senate approved a handful of amendments by unanimous consent on Wednesday (see below), and will hold about a dozen votes before coming to the final bill. The legislation, S. 3187, is generally non-controversial, and would reauthorize and extend a user-fee program that drug and medical device industry groups support as a way of speeding up the FDA approval process.
As part of a deal announced Wednesday, Republicans won the right to have a vote on their alternative plan, which would terminate a preventive health fund created in 2010.
But approval of both the GOP alternative and the Democratic bill will need 60 votes to pass. Because each party seems to genuinely hate the other's bill, the votes might well be a setup for partisan finger-pointing once both fail, which will at least give the parties something to talk about over the long Memorial Day weekend.
The Senate should also approve a 60-day extension of the National Flood Insurance Program at some point today. Senate Majority Leader Harry ReidHarry ReidThis obscure Senate rule could let VP Mike Pence fully repeal ObamaCare once and for all Sharron Angle to challenge GOP rep in Nevada Fox's Watters asks Trump whom he would fire: Baldwin, Schumer or Zucker MORE (D-Nev.) said Wednesday that he would agree to tackle a longer-term reform bill once the Senate returns from its Memorial Day week off.
Also up today, a likely vote on a bill to extend the National Flood Insurance Program (NFIP) for 60 days, also part of Wednesday's announcement.
In a unanimous-consent vote Wednesday, the Senate approved H.R. 4097, the John F. Kennedy Center Reauthorization Act, and the following six amendments to the FDA bill, from:
• Sen. Ben CardinBen CardinSenators introduce new Iran sanctions Senate confirms Trump's pick for Israel ambassador Rand Paul roils the Senate with NATO blockade MORE (D-Md.), to ensure that adequate information is disseminated to healthcare providers and payers about the potential benefits and risks of medical products on all patient populations, particularly underrepresented sub-populations, including racial subgroups;
• Cardin, to require the commissioner of Food and Drugs to report to Congress on issues with respect to small businesses;
• Sen. Chuck GrassleyChuck GrassleyFriends, foes spar in fight on Trump’s Supreme Court nominee Live coverage: Day three of Supreme Court nominee hearing Live coverage: Day two of Supreme Court nominee hearing MORE (R-Iowa), to provide employee protections for the Commissioned Corps of the Public Health Service Act;
• Grassley, to provide deadlines for the issuance of certain regulations and to require a GAO report on the implementation of the clinical trial registration and reporting requirements under the Public Health Service Act;
• Sen. Joe ManchinJoe ManchinSenate confirms Trump's pick for Israel ambassador Senate Dems: We won't help pass additional health bills RNC drops six-figure ad buy for Supreme Court, healthcare fight MORE (D-W.Va.), to reclassify the pain reliever hydrocodone under the Controlled Substances Act; and
• Sen. Jack ReedJack ReedSenators demand Pentagon action after nude photo scandal Mattis on defense budget boost: 'America can afford survival' Overnight Regulation: Dems punch back in fight over CEO pay rule MORE (D-R.I.), to make effective the proposed rule of the Food and Drug Administration relating to sunscreen drug products.